- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05930093
Avalie a eficácia e a segurança das cápsulas LivPhcD em indivíduos com DHGNA
Estudo multicêntrico, randomizado, duplo-cego, controlado por placebo para avaliar a eficácia e a segurança das cápsulas de LivPhcD em indivíduos com DHGNA
Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse. Early-stage NAFLD does not usually cause any harm but nonalcoholic steatohepatitis (NASH) can lead to serious liver damage, including fibrosis or cirrhosis. Nearly 25% of the world's population is affected by NAFLD.
There are no FDA-approved medications for the treatment of NAFLD currently and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients.
LivPhcD™ capsule have shown hepatoprotective effects in both animal and human data. This study aims to investigate the effects of LivPhcD™ capsule in hepatocellular lipid content using Fibroscan.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Not Required For This Country
-
Taipei, Not Required For This Country, Taiwan, 221
- National Taiwan University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or female between 20 and 75 years of age.
- Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
- Has a body mass index (BMI) ≥20 kg/m^2 and ≤50 kg/m^2 and stable weight for the past 3 months
- CAP ≥ 238 db/m
- Fibro scan (transient elastography) F0~F3
Exclusion Criteria:
- Pregnant or breastfeeding or planning to become pregnant or unwilling to use an acceptable contraceptive method to avoid pregnancy during the study period
- Type 1 diabetes mellitus.
- History of other causes of chronic liver disease [autoimmune, primary biliary cirrhosis, HBV (HBsAg positive) and HCV, Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.
- Use of medications that could induce steatosis, such as estrogen or other hormonal replacement therapy, amiodarone, methotrexate, tamoxifen, raloxifene, pharmacological doses of oral glucocorticoids (≥10 mg per day of prednisone or equivalent), or chloroquine.
- Use of vitamin E (doses ≥800 IU/dy) or pioglitazone or SGLT2 inhibitor or GLP-1 agonists any FDA-approved drug for NASH to be approved during the study.
- Has significant systemic or major illnesses other than liver disease, ex: recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, serious COPD, renal failure and need hemodialysis, stroke, transient ischemic attack, or organ transplantation
- Known alcohol abuse or alcohol use disorder (>20 g/day for women; >30 g/day for men)
- Has the abnormal data including: fasting TG >400 mg/dL ; ALT or GGT>5.0 x ULN;Bilirubin >2 x ULN,unless due to an alternative etiology such as Gilbert's syndrome; INR ≥1.3; Albumin < LLN; Platelet <0.95x LLN
- Subjects with hemoglobin A1c (HbA1c) >8.5% within 3 months before study entry
- Plan to have major surgery during the study period (bariatric surgery, biliary diversion surgery)
- Participation in any other investigational clinical trial within 30 days of entry to this protocol(including drugs, medical devices, novel medical technologies, food, and lifestyle interventions affecting diet, exercise, and circadian rhythm investigational clinical trial.);
- History of HIV
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
Placebo without active ingredient |
Placebo matching LivPhcD cap. |
|
Comparador Ativo: 2 cap.LivPhcD/per day
515mg/LivPhcD cap. 2 cap./per day |
2 caps. LivPhcD cap. after meal, once a day |
|
Comparador Ativo: 4 cap.LivPhcD/per day
515mg/LivPhcD cap. 4 cap./per day, BID |
4 caps. LivPhcD cap. after meal, BID |
|
Comparador Ativo: 6 cap.LivPhcD/per day
515mg/LivPhcD cap. 6 cap./per day, TID |
6 caps. LivPhcD cap. after meal, TID |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Reduction of Liver Fat
Prazo: 36 weeks
|
Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fat by CAP(Controlled Attenuation Parameter) |
36 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in liver fat at least 30% reduction
Prazo: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with ≥ 30% reduction of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fat at least 1 stage reduction
Prazo: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fat
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change of liver fat by CAP |
24 weeks and 36 weeks
|
|
Stable in liver fat
Prazo: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with stable of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fibrosis at least 10% reduction
Prazo: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Change in liver fibrosis at least 1 stage reduction
Prazo: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Stable in liver fibrosis
Prazo: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with stable reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Change in liver fibrosis
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change of FIB-4 |
24 weeks and 36 weeks
|
|
Change in ALT
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of ALT |
24 weeks and 36 weeks
|
|
Change in AST
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of AST |
24 weeks and 36 weeks
|
|
Change in GGT
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of GGT |
24 weeks and 36 weeks
|
|
Change in AP
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of AP |
24 weeks and 36 weeks
|
|
Change in Bilirubin
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Bilirubin |
24 weeks and 36 weeks
|
|
Change in Triglyceride
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Triglyceride |
24 weeks and 36 weeks
|
|
Change in Total Cholesterol
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Total Cholesterol |
24 weeks and 36 weeks
|
|
Change in HDL-C
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of HDL-C |
24 weeks and 36 weeks
|
|
Change in LDL-C
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of LDL-C |
24 weeks and 36 weeks
|
|
Change in TNF-α
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of TNF-α |
24 weeks and 36 weeks
|
|
Change in C-Reactive Protein
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of C-Reactive Protein |
24 weeks and 36 weeks
|
|
Change in Albumin
Prazo: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Albumin |
24 weeks and 36 weeks
|
|
Occurrence of adverse events and serious adverse events
Prazo: 24 weeks and 36 weeks
|
Between group difference in the occurrence of adverse events and serious adverse events. |
24 weeks and 36 weeks
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- LivPhcD-001
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .